During consultations, the question often sounds very simple: “I was offered Radiesse and Sculptra. Which is better?” This wording is exactly what most often leads people off track. CaHA and PLLA are both classified as collagen biostimulators, but they are not two versions of the same procedure. They have different material structures, behave differently after injection, and create different timelines for results.
This is well illustrated by a small comparative study involving five women. PLLA was injected into the left hand, while hyperdiluted CaHA was injected into the right. After the first session, the CaHA-treated side looked better in three participants. By the end of the course, two participants showed a more pronounced result with PLLA, but the researchers found no overall clinical advantage of one material over the other. The sample was very small, and the hands, not the face, were assessed. Still, this example accurately conveys the main challenge of comparison: the conclusion depends on the tissue, protocol, number of procedures, and timing of assessment.
Short answer: CaHA is more often considered when early structural support is needed in a specific area, together with subsequent tissue remodeling. PLLA is usually chosen for gradual correction planned in several stages and not evaluated immediately after injection. The right choice does not begin with searching for the “stronger” product, but with defining the specific anatomical task.
Why can’t CaHA and PLLA be compared only by duration?
The term “collagen biostimulator” can create the impression that the product merely sends a useful signal to the tissues, after which the body does all the work on its own. In reality, the physician injects a material that physically remains in the tissues for a certain period and triggers a controlled biological response. This response involves inflammatory cells, fibroblasts, the extracellular matrix, and the gradual breakdown of particles.
That is why the result is not determined by the name of the substance alone. Particle shape and size, carrier composition, concentration, injection plane, distribution method, tissue condition, and an individual person’s response all matter. A marketing figure for duration does not explain which material is better suited to a particular area or expected scale of change.
“Both PLLA and CaHA demonstrated significant improvements in skin elasticity, wrinkle reduction, and increased facial volume.”
Systematic review by Ferreira et al.
This quote confirms that both materials can produce a clinically noticeable effect. It does not mean that CaHA and PLLA behave the same way in tissues or can replace each other in any protocol.
How do the materials and tissue response differ?
CaHA: microspheres in a gel carrier
In the U.S. instructions for RADIESSE, the product is described as synthetic calcium hydroxylapatite microspheres measuring 25–45 microns, suspended in a cohesive gel made of water, glycerin, and sodium carboxymethylcellulose. The gel carrier provides an early mechanical contribution, so a change may be visible even before remodeling processes have fully unfolded.
Undiluted, diluted, and hyperdiluted CaHA should not be perceived as the same procedure with different amounts of water. The particle concentration, viscoelastic properties, distribution method, and clinical goal all change. In one case, the physician may aim for local structural support; in another, for a more even improvement in tissue quality.
PLLA: particles injected as a suspension
Sculptra is supplied as a lyophilized material containing poly-L-lactic acid microparticles, sodium carboxymethylcellulose, and mannitol. Before the procedure, the product is reconstituted with sterile water, and lidocaine may be added according to the instructions.
The injected liquid creates initial fullness, but this is not the final PLLA result. The water distributes and is resorbed, after which visible changes develop gradually. That is why in the first few days a person may see a pronounced effect, then notice it decreasing and mistakenly conclude that the product “didn’t work.”
A morphological study showed predominantly uniform spherical CaHA-CMC particles and PLLA particles that were much more heterogeneous in shape and size. This difference does not prove the superiority of one product, but it does confirm that these are not identical materials in different packaging.
The structural difference would be merely a laboratory detail if it did not change what a person sees after the procedure. But the physical form of the product is partly what determines why the early appearance after CaHA and PLLA should be interpreted differently.
How does the result develop after each product?
After CaHA, the initial change may be noticeable due to the gel carrier and mechanical tissue support. How pronounced this contribution will be depends on the concentration, volume, plane, area, and injection technique. The early effect then changes, while gradual remodeling comes to the forefront.
After PLLA, the first appearance is largely shaped by the water used for reconstitution, local swelling, and the injection response itself. When this fullness decreases, a person may interpret normal dynamics as a loss of effect. PLLA should be assessed according to an agreed schedule of follow-up visits, not based on a photo taken the evening after the procedure.
| Criterion | CaHA | PLLA |
|---|---|---|
| Product form | Microspheres in a cohesive gel carrier | Lyophilized material reconstituted into a suspension |
| What shapes the early appearance | Gel carrier and mechanical tissue support | Fluid, swelling, and the injection response |
| Development of the result | Early contribution is combined with subsequent remodeling | Changes develop gradually after the initial fullness decreases |
| Typical treatment goal | Local support or work on tissue quality, depending on the protocol | Gradual correction of a broader area |
| Planning | Depends on concentration, area, plane, and technique | More often involves several stages with interim assessment |
This is where one of the most common mistakes arises: early fullness after PLLA is taken for the future result, while the early effect of CaHA is taken for its final action. The general logic of this dynamic is explained in the article “Why results in cosmetology are not linear: how the effect of procedures changes over time”.
For which tasks might a physician choose CaHA or PLLA?
When may CaHA be considered?
CaHA may be a logical choice when it is necessary to support a specific area while simultaneously initiating gradual tissue remodeling. In diluted and hyperdiluted protocols, the focus may shift from local projection to firmness, density, and the overall appearance of the skin.
This does not mean that CaHA is automatically suitable for any area where “more density” is desired. The physician must consider the thickness of the overlying tissues, the mobility of the area, vascular anatomy, previous injections, and whether a precise structural change is truly needed.
When may PLLA be considered?
PLLA is more often discussed with people who are ready for a delayed result, several stages, and gradual correction. This approach may be appropriate when the task is not about one small point, but about a broader change in support or tissue quality.
PLLA is less suited to the expectation of obtaining a precisely defined local shape after one visit. Age alone does not determine the choice: skin condition, tissue thickness, loss of support, photodamage, anatomical proportions, and previous injection history are all important.
In brief for search: CaHA is more often chosen for tasks where early support and controlled distribution in a specific area are important. PLLA is more often used in gradual correction plans, where the result is assessed after a series of stages. The final decision depends on the tissues, protocol, and registered product.
What limitations of evidence and risks should be considered?
In the systematic review, the effect of PLLA in some of the included studies lasted up to 25 months, while for CaHA, approximately 12–18 months was often described. But these figures cannot be interpreted as a direct duel between the products. The studies differed in products, areas, number of procedures, injection techniques, assessment criteria, and follow-up duration.
“To date, there have been no randomized-controlled-trials comparing the efficacy of PLLA vs CaHa-R for skin rejuvenation in the face and body.”
ClinicalTrials.gov, record NCT07202117
The practical conclusion from this quote is simple: claims of the overall superiority of one material over the other are ahead of the available direct comparative evidence.
What early reactions are possible?
After both procedures, pain, redness, swelling, bruising, tenderness, and temporary unevenness may occur. Some of these manifestations are related not only to the material, but also to the puncture, fluid volume, number of needle or cannula passes, and tissue trauma. As with any transdermal injection, there is a risk of infection.
Why is vascular safety important?
Intravascular injection of an injectable material can cause occlusion, ischemia, necrosis, or embolic complications. The term “biostimulator” does not automatically make the procedure safe. Knowledge of anatomy, choice of plane, technique, and readiness to immediately recognize dangerous symptoms all matter.
Why can papules and nodules occur?
Delayed subcutaneous papules and nodules have been described with PLLA and may appear days or months later. Nodules, induration, migration, and inflammatory reactions are also known with CaHA. Injection that is too superficial or an incorrect choice of area increases the risk of visible unevenness.
“The safety and effectiveness of RADIESSE for use in the lips has not been established.”
FDA, RADIESSE instructions
This quote refers to the specific U.S. instructions for RADIESSE, not to all CaHA products in every country. However, it illustrates a broader principle: the popularity of off-label use is not the same as confirmed safety.
CaHA and PLLA are not hyaluronic acid-based fillers. Hyaluronidase does not dissolve them the way it dissolves hyaluronic acid products, so an error in volume, area, or plane does not have the same rapid correction scenario. The possibilities and limitations of the enzyme are discussed in more detail in the article “Hyaluronidase in aesthetic medicine: when it is needed and why it should not be feared”.
If a person does not remember what was injected previously, has induration, prolonged swelling, or a complex injection history, ultrasound diagnostics may provide additional information. The article “Ultrasound before fillers: when it is needed and how it improves procedure safety” explains in which situations imaging truly changes the decision.
How is the decision made during a consultation?
In a good consultation, the patient is not simply told “CaHA” or “PLLA.” They are told which tissue is planned to be changed, why the chosen material matches this task, when to expect the result, and what limitations the proposed plan has.
- What is the exact commercial name of the product, and is it registered for this task?
- What anatomical or tissue-related problem is the procedure meant to solve?
- Why has CaHA or PLLA specifically been chosen in this case?
- What CaHA concentration or PLLA reconstitution scheme is planned?
- What will be visible in the first few days, and when should the main result realistically be assessed?
- How many stages may be needed, and by what criteria will the next one be scheduled?
- Do previous fillers, biostimulators, or device-based procedures affect the plan?
- Which symptoms require urgent contact, and how does the clinic act in the event of a complication?
The right question is not “which biostimulator is better?” but “which material matches my tissue-related task, anatomy, timeframe, and acceptable level of risk?” If there is no clear answer to these points during the consultation, choosing a product based only on its name or promised duration is not advisable.
